This content is machine translated Heart failure SGTL2 inhibitor shows clinically meaningful effect in HFpEF. Diastolic heart failure is the spectre of cardiology. To date, there is no conclusive therapy concept that improves the poor prognosis of those affected. Many hopeful treatment approaches were investigated and…
View Post 3 min This content is machine translated SGLT2 inhibitors Cardioprotective effect proven and found to be good – a statement One of the serious long-term consequences of diabetes mellitus is cardiovascular disease. Heart failure, in particular, is common in patients who have had diabetes for a long time. Recent study…
View Post 2 min This content is machine translated Heart failure SGLT2 inhibitors improve cardiovascular risk SGLT2 inhibitors are used with great success as antidiabetic agents. However, new study data revealed a positive side effect: the drug group appears to have additional cardioprotective as well as…
View Post 3 min This content is machine translated SGLT2 inhibitors Protective effects of dapagliflozin in heart failure patients. From the large cardiovascular endpoint studies EMPA-REG, CANVAS, and DECLARE, it is clear that SGLT2 inhibitors have a beneficial effect on heart failure. This was confirmed in the DAPA-HF study.
View Post 7 min This content is machine translated Epidemology and current study situation Diabetes mellitus and risk of infection 2016 The most common infections affect the skin and genitourinary tract. Infections occur more frequently above an HbA1c >8.5%. SGLT2 inhibitors are effective in the treatment of type 2 diabetes mellitus,…
View Post 3 min This content is machine translated SGIM Congress in Basel Diabetes update – what do you need to know about the different agents? A lot has happened in the field of diabetes therapy in recent years. Many new active ingredients have appeared on the market. However, metformin and lifestyle modifications are still considered…
